Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Alterity PBT434 Poster Presented at 2019 MDS Congress

October 3, 2019August 16, 2022 Alterity Therapeutics

Alterity PBT434 Poster – MDS 2019 Congress

2019

Post navigation

Alterity presents clinical data on PBT434 at the 2019 MDS Congress

Quarterly Cash Flow Report

Related Posts

Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

April 17, 2024March 10, 2025

Appendix 4C – Q2 FY23 Quarterly Cash Flow Report

January 31, 2023May 23, 2023

Prana Completes Recruitment in Huntington Trial

July 17, 2013August 16, 2022

Recent Posts

Alterity Therapeutics Prominently Featured at the International MSA Congress
Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
Appendix 4C – Q3 FY25 Quarterly Cash Flow Report
Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065